Your session is about to expire
← Back to Search
Rocatinlimab for Eczema (ROCKET-Horizon Trial)
ROCKET-Horizon Trial Summary
This trial compares a new drug to placebo to see if it helps reduce eczema symptoms.
ROCKET-Horizon Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2018 Phase 2 trial • 66 Patients • NCT02647866ROCKET-Horizon Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I haven't used any strong skin medications or treatments in the last week.I haven't taken steroids, immunosuppressants, had phototherapy, or used Janus kinase inhibitors recently.I often feel itchy, rating my itchiness at least a 4 out of 10.At least 10% of my skin is affected by my condition.My skin condition didn't improve with strong creams or ointments.I haven't taken any biological medication for the last 12 weeks or 5 half-lives, whichever is longer.I am an adult diagnosed with AD for at least a year.I've used strong skin creams for my condition without improvement in the last 6 months.
- Group 1: Rocatinlimab
- Group 2: Placebo
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are seniors over the age of 85 able to partake in this experimentation?
"As specified by the clinical trial's inclusion criteria, only patients aged 18-100 are eligible. Separately, 102 trials and 168 trials have been created for individuals younger than 18 and over 65 respectively."
Has enrollment for this therapeutic trial been opened up?
"Correct. The information posted on clinicaltrials.gov affirms that this medical trial, first published on December 14th 2022, is still recruiting patients. Approximately 680 individuals need to be enrolled from 6 differing locations."
Has Rocatinlimab been endorsed by the FDA?
"Rocatinlimab has been assessed with a rating of 3 due to the presence of data evidencing its efficacy and multiple iterations of safety-related research."
Are there numerous facilities offering this trial in the North American region?
"Patients wishing to take part in this clinical trial can enrol at Clinical Science Institute (Santa Monica, California), St. Jude Clinical Research (Doral, Florida) and Kentucky Advanced Medical Research LLC (Murray, Kentucky). There are 6 other additional sites taking patients as well."
What is the aggregate amount of participants enrolled in this trial?
"Affirmative. According to clinicaltrials.gov, this medical experiment is actively seeking individuals for its study; it was initially announced on December 14th 2022 and underwent a recent alteration on the 16th of that same month. 680 participants are needed from 6 distinct locations."
Do I meet the prerequisites to partake in this medical experiment?
"This trial requires 680 adults (18 and above) with a 6-month history of dermatitis that has proven ineffective to mid or higher potency topical corticosteroids, as well as an EASI score ≥16, vIGA-AD score≥3, worst pruritus numerical rating scale ≥4, and BSA involvement of at least 10%."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger